Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nathanael Gray, Ph.D.

Co-Author

This page shows the publications co-authored by Nathanael Gray and John Hatcher.
Connection Strength

6.320
  1. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Nov 12; 11(11):2238-2243.
    View in: PubMed
    Score: 0.931
  2. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. ACS Med Chem Lett. 2018 Jun 14; 9(6):540-545.
    View in: PubMed
    Score: 0.780
  3. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol. 2018 04 19; 25(4):460-470.e6.
    View in: PubMed
    Score: 0.776
  4. Small-Molecule Inhibitors of LRRK2. Adv Neurobiol. 2017; 14:241-264.
    View in: PubMed
    Score: 0.717
  5. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81.
    View in: PubMed
    Score: 0.678
  6. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem. 2015 Dec 10; 58(23):9296-9308.
    View in: PubMed
    Score: 0.664
  7. Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2015 May 14; 6(5):584-9.
    View in: PubMed
    Score: 0.636
  8. Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angew Chem Int Ed Engl. 2020 08 10; 59(33):13865-13870.
    View in: PubMed
    Score: 0.227
  9. Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorg Med Chem Lett. 2019 07 15; 29(14):1694-1698.
    View in: PubMed
    Score: 0.211
  10. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorg Med Chem Lett. 2019 06 01; 29(11):1336-1339.
    View in: PubMed
    Score: 0.209
  11. Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2012 Aug 09; 3(8):658-662.
    View in: PubMed
    Score: 0.131
  12. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020 12 10; 183(6):1714-1731.e10.
    View in: PubMed
    Score: 0.059
  13. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nat Commun. 2019 10 18; 10(1):4741.
    View in: PubMed
    Score: 0.054
  14. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chem Biol. 2019 11 21; 26(11):1486-1500.
    View in: PubMed
    Score: 0.054
  15. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). J Biol Chem. 2019 03 22; 294(12):4511-4519.
    View in: PubMed
    Score: 0.052
  16. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest. 2018 10 01; 128(10):4397-4412.
    View in: PubMed
    Score: 0.050
  17. Crystal structure of human IRAK1. Proc Natl Acad Sci U S A. 2017 12 19; 114(51):13507-13512.
    View in: PubMed
    Score: 0.048
  18. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chem Biol. 2015 Dec 18; 10(12):2687-96.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.